PGI Is Contemplating To Start In-House Testing Of Medicines

CHANDIGARH : After the recent cases of drug contamination and adverse events at PGI, the institute is contemplating to start in-house testing of medicines, a facility lacking in any public hospital in the country.

There are regional and central drugs laboratories and some private centres which are approved by the DCGI to test and analyse suspected medicine samples. No hospital has the large scale facility or infrastructure for testing medicine safety and efficacy.

“We are actively working on it. It should be operational sooner than later. It will be a double check. We will not have to depend on outside resources,” said Prof Vivek Lal, director, PGI.

After five deaths of patients who were to be operated upon and were administered sedative drug Propofol, the PGI had sent the samples of the medicine to the drug control authorities in the city. It took almost a month for the test analysis report. With the in-house testing, the hospital will be able to conclude with evidence if the adverse event was due to the medicines or other complications.

“The sample was also tested by the pharmacology department in the PGI and in Panjab University. But in the absence of the requisite infrastructure/reagents, the test was not as validated as from the approved government testing laboratories,” said a faculty member at PGI.

The laboratory will follow pharmacopoeia monographs — documents which are taken as reference for testing of drugs — and had to be good manufacturing practice compliant. “When the facility is ready, suspected drugs will be tested here prior to giving it to the patients who are admitted for surgery or for treatment. However, for any legal action, the samples will also be sent to the approved government laboratories,” said a senior faculty member.

  • Related Posts

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre